XEROX CORP 4
4 · XEROX CORP · Filed Aug 13, 2013
Insider Transaction Report
Form 4
XEROX CORPXRX
BLODGETT LYNN
Executive Vice President
Transactions
- Exercise/Conversion
Common Stock
2013-08-12$7.10/sh+152,358$1,081,742→ 355,325 total - Sale
Common Stock
2013-08-12$10.13/sh−69,776$706,803→ 202,967 total - Exercise/Conversion
Common Stock
2013-08-12$7.33/sh+47,642$349,216→ 250,609 total - Sale
Common Stock
2013-08-12$10.13/sh−47,642$482,594→ 202,967 total - Exercise/Conversion
Stock Options
2013-08-12−152,358→ 0 totalExercise: $7.10From: 2010-02-05Exp: 2017-08-15→ Common Stock (152,358 underlying) - Exercise/Conversion
Stock Options
2013-08-12−47,642→ 660,886 totalExercise: $7.33From: 2010-02-05Exp: 2014-07-30→ Common Stock (47,642 underlying) - Sale
Common Stock
2013-08-12$10.07/sh−82,582$831,237→ 272,743 total
Footnotes (4)
- [F1]Weighted average prices of shares sold. Shares sold in the range of $9.99- $10.14.
- [F2]Weighted average price of shares sold. Shares sold in the range of $10.1 - $10.1312
- [F3]Weighted average price of shares sold. Shares sold in the range of $10.1315 - $10.1598
- [F4]These options vest and become excercisable as follows: on each anniversary date of the grant, commencing with the first such anniversary date and continuing on each such anniversary thereafter through and including the fifth anniversary of the date of the grant, 20% of such options shall vest and become excercisable. The date of the grant is 10 years prior to the stated expiration date.